UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial

Leukemia & lymphoma, 2017-05, Vol.58 (5), p.1084-1093

2017

Volltextzugriff (PDF)

Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

International journal of oncology, 2015-03, Vol.46 (3), p.1259-1267

2015

Volltextzugriff (PDF)

Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro

Journal of chemistry, 2015-01, Vol.2015, p.1-11

2015

Volltextzugriff (PDF)

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors

Molecular medicine reports, 2019-05, Vol.19 (5), p.3593-3603

2019

Volltextzugriff (PDF)

In vitro antileukemic activity of novel adenosine derivatives bearing boron cluster modification

Bioorganic & medicinal chemistry, 2016-11, Vol.24 (21), p.5076-5087

2016

Volltextzugriff (PDF)

Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL

Leukemia & lymphoma, 2017-07, Vol.58 (7), p.1598-1606

2017

Volltextzugriff (PDF)

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

European journal of haematology, 2007-08, Vol.79 (2), p.107-113

2007

Volltextzugriff (PDF)

The differences in thermal profiles between normal and leukemic cells exposed to anticancer drug evaluated by differential scanning calorimetry

Journal of thermal analysis and calorimetry, 2014-11, Vol.118 (2), p.1339-1344

2014

Volltextzugriff (PDF)

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development

Oncology letters, 2017-04, Vol.13 (4), p.2079-2084

2017

Volltextzugriff (PDF)

Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application

Mini reviews in medicinal chemistry, 2007-09, Vol.7 (9), p.976-983

2007

Volltextzugriff (PDF)

Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia

Postȩpy higieny i medycyny doświadczalnej, 2016-12, Vol.70, p.1321-1330

2016

Volltextzugriff (PDF)

Roscovitine Triggers Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells with Similar Efficiency as Combinations of Conventional Purine Analogs with Cyclophosphamide

Annals of the New York Academy of Sciences, 2009-08, Vol.1171 (1), p.124-131

2009

Volltextzugriff (PDF)

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis

Journal of cellular biochemistry, 2010-01, Vol.109 (1), p.217-235

2010

Volltextzugriff (PDF)

Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases

Cancer biology & therapy, 2013-01, Vol.14 (1), p.6-12

2013

Volltextzugriff (PDF)

Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study

Pharmacological reports, 2012, Vol.64 (2), p.412-420

2012

Volltextzugriff (PDF)

Promising anti-leukemic activity of atorvastatin

Oncology reports, 2013-05, Vol.29 (5), p.2065-2071

2013

Volltextzugriff (PDF)

Antibody Therapy Alone and in Combination with Targeted Drugs in Chronic Lymphocytic Leukemia

Seminars in oncology, 2016-04, Vol.43 (2), p.280-290

2016

Volltextzugriff (PDF)

In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent

Pharmacological reports, 2013, Vol.65 (2), p.460-475

2013

Volltextzugriff (PDF)

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment

Medical oncology (Northwood, London, England), 2012-09, Vol.29 (3), p.2111-2126

2012

Volltextzugriff (PDF)

Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status

Leukemia & lymphoma, 2019-05, Vol.60 (6), p.1409-1419

2019

Volltextzugriff (PDF)

Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance

European journal of haematology, 2014-02, Vol.92 (2), p.91-101

2014

Volltextzugriff (PDF)

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia

Mediators of Inflammation, 2003-06, Vol.2003 (3), p.167-171

2003

Volltextzugriff (PDF)

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1)

Medical science monitor, 2005-10, Vol.11 (10), p.PI71

2005

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(77)

Sprache

Englisch
(77)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(52)
Humans
(51)
Aged
(41)
Male
(41)
Female
(40)
Middle Aged
(40)
Oncology
(31)
Hematology
(28)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(27)
Aged, 80 And Over
(25)
Chronic Lymphocytic Leukemia
(24)
Adult
(23)
Cladribine - Administration & Dosage
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Leukemia, Lymphocytic, Chronic, B-Cell - Pathology
(19)
Cyclophosphamide - Administration & Dosage
(16)
Cladribine
(14)
Treatment Outcome
(14)
Apoptosis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Leukemia & Lymphoma
(15)
Blood
(14)
Cancer Biology & Therapy
(4)
European Journal Of Haematology
(4)
Leukemia Research
(4)
Mediators Of Inflammation
(4)
Oncology Reports
(3)
Postȩpy Higieny I Medycyny Doświadczalnej
(3)
Cancer
(2)
Oncology Letters
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial

Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors

In vitro antileukemic activity of novel adenosine derivatives bearing boron cluster modification

Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL

Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

The differences in thermal profiles between normal and leukemic cells exposed to anticancer drug evaluated by differential scanning calorimetry

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development

Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application

Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia

Roscovitine Triggers Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells with Similar Efficiency as Combinations of Conventional Purine Analogs with Cyclophosphamide

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis

Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases

Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study

Promising anti-leukemic activity of atorvastatin

Antibody Therapy Alone and in Combination with Targeted Drugs in Chronic Lymphocytic Leukemia

In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment

Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)

Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1)

Suchergebnisse filtern